However, our genotype–phenotype integrated diagnoses based on the 2021 WHO classification of CNS tumors were not as relevant to the genotypes as neuroimaging features; the most frequent diagnosis was MAPK pathway-altered dLGG in both BRAF V600E and FGFR1 mutations. This evidence concerns the gene FGFR1 and central nervous system neoplasm.